Estrogen Receptors and Endometriosis

Elodie Chantalat 1,2,4, Marie-Cécile Valera 2,*,†, Charlotte Vaysse 1, Emmanuelle Noirrit 2, Mariam Rusidze 2, Ariane Weyl 1, Kelig Vergriete 1, Etienne Buscail 3, Philippe Lluel 4, Coralie Fontaine 2, Jean-François Arnal 2 and Françoise Lenfant 2

1 IUCT Oncopole, 31100 Toulouse, France
2 INSERM-UPS UMR U1048, Institut des Maladies Métaboliques et Cardiovasculaires, Université de Toulouse, BP 84225, CEDEX 04, 31 432 Toulouse, France
3 Department of Visceral Surgery, CHU Rangueil, 31400 Toulouse, France
4 Urosphere, Rue des Satellites, 31400 Toulouse, France
* Correspondence: marie.valera@inserm.fr
† These authors contributed equally to this work.

Received: 28 February 2020; Accepted: 15 April 2020; Published: 17 April 2020

Abstract: Endometriosis is a frequent and chronic inflammatory disease with impacts on reproduction, health and quality of life. This disorder is highly estrogen-dependent and the purpose of hormonal treatments is to decrease the endogenous ovarian production of estrogens. High estrogen production is a consistently observed endocrine feature of endometriosis. mRNA and protein levels of estrogen receptors (ER) are different between a normal healthy endometrium and ectopic/eutopic endometrial lesions: endometriotic stromal cells express extraordinarily higher ERβ and significantly lower ERα levels compared with endometrial stromal cells. Aberrant epigenetic regulation such as DNA methylation in endometriotic cells is associated with the pathogenesis and development of endometriosis. Although there is a large body of data regarding ERs in endometriosis, our understanding of the roles of ERα and ERβ in the pathogenesis of endometriosis remains incomplete. The goal of this review is to provide an overview of the links between endometriosis, ERs and the recent advances of treatment strategies based on ERs modulation. We will also attempt to summarize the current understanding of the molecular and cellular mechanisms of action of ERs and how this could pave the way to new therapeutic strategies.

Keywords: endometriosis; estrogen receptors; modulation; treatment strategy

1. Introduction

Endometriosis is one of the most frequently encountered benign gynecological diseases, known to occur in 6–10% of women of reproductive age [1,2]. It is an estrogen-dependent gynecological condition, defined as the presence and growth of endometrial-like tissue outside the uterine cavity [3]. Initially, three forms of endometriosis were classified according to their location: ovarian endometrioma (OMA), superficial peritoneal lesions (SUP) and deep subperitoneal infiltrating endometriosis (DIE) [4]. A fourth form that was frequently associated is internal endometriosis, since it is represented by the endometrium present within the myometrium (adenomyoma) (Figure 1). The most common locations for the ectopic endometrial implants are the ovaries, the fossa ovarica, the uterosacral ligaments, the posterior cul-de-sac, the rectum and sigmoid (20%) and more rarely in the pericardium, pleura and even the brain [5].
This infertility is often multifactorial including implantation disorders, pelvic adhesions and ovarian insufficiency, linked to the endometriomas altering the ovarian parenchyma. Endometriosis is therefore one of the most severe benign gynecological diseases because of its major consequences on fertility, daily quality of life with an alteration in sexual life and professional absenteeism [8–10].

Endometriosis may give a wide array of symptoms ranging from pelvic pain (75% of cases) to catamenial pneumothorax but is mainly associated with severe and chronic pain, dysmenorrhea and deep dyspareunia as well as problems with fertility, although asymptomatic cases do arise [6]. The most evocative argument in favor of endometriosis is its cyclicity since it occurs very frequently during menstruation (catamenial pain) or in the peri-ovulatory period. Endometriosis is found in 25% to 40% of infertile patients and the risk of infertility is increased by 10 in case of endometriosis [7]. This infertility is often multifactorial including implantation disorders, pelvic adhesions and ovarian insufficiency, linked to the endometriomas altering the ovarian parenchyma. Endometriosis is therefore one of the most severe benign gynecological diseases because of its major consequences on fertility, daily quality of life with an alteration in sexual life and professional absenteeism [8–10].

Endometriosis is stratified by the American Society for Reproductive Medicine (ASRM) classification into four stages (I, II, III and IV) according to surgical evaluation of the size, location and severity of the endometriotic lesions and the occurrence of extensions of adhesions [11]. Other classifications, such as the European classification giving the FOATI score (Peritoneal focus-Endometrioma-Adherence-Tube-Inflammation), or the endometriosis fertility index (EFI) score, assess peritoneal inflammation as well as the progression of the disease and the rate of pregnancy obtained by in vitro fertilization after surgical treatment of endometriosis, respectively [12]. The definitive diagnosis for endometriosis is based on laparoscopy with biopsy followed by histological analysis. However, non-invasive diagnosis and markers of endometriosis that can confirm diagnosis are needed for treatment planning. Among imaging procedures, the magnetic resonance imaging (MRI) appears as the possibility to perform a complete assessment of all the pelvic compartments at one time. It therefore represents a good imaging technique for the preoperative staging of endometriosis [13].

Apart from the painful symptomatology of the disease, which is incapacitating [14,15], the morbidities of surgical management such as pelvic abscesses, rectovaginal fistulas and peritonitis participate in the alteration of quality of life [16]. For women with pain, surgery commonly provides temporary relief, although symptoms recur in up to 75% of women within two years, and further surgery is needed in many cases [1,17]. Medical treatment is often the first-line therapeutic option. Medical therapies historically have included combined oral contraceptives, progestagens, and agonists of gonadotropin-releasing hormone (GnRH), as well as androgens and non-hormonal treatments, such as painkillers and non-steroidal anti-inflammatory agents. Hormonal treatments for endometriosis focus on suppressing hormonal fluctuations (gonadotropin and ovarian hormones), resulting in the

---

Figure 1. Schematic lateral view of the pelvis illustrating the 4 forms of endometriosis: 1: endometrioma (OMA); 2: superficial peritoneal endometriosis (SUP); 3: deep subperitoneal infiltrating endometriosis (DIE); 4: adenomyoma (Ad).
inhibition of ovulation and menstruation and a downstream decrease in inflammation. Hormonal treatment alone does not provide long-term disease control because it is often interrupted due to a significant amount of untoward side effects [18].

While the etiology of endometriosis still remains unclear, retrograde menstruation, in which uterine epithelial and stromal cells are disseminated and implanted into the peritoneal cavity via the fallopian tubes, is the most accepted mechanism for the pathogenesis of endometriosis. However, there is a missing link because the majority of women have retrograde menstruation (90% of women) but only 5% to 10% of women of reproductive age and 2.5% of postmenopausal women will develop lesions of endometriosis [1,19]. Moreover, retrograde menstruation does not explain the occurrence of endometriosis in extra pelvic locations. A second theory about the mechanism of the onset of endometriosis suggests that the epithelial peritoneal lining might transform into endometrial tissue under the influence of stimuli: this is the theory of coelomic metaplasia [20,21]. Another theory, of the benign lymphatic or haematogenous metastases, proposes an extraperitoneal dissemination of endometrial tissue via the lymphatic ducts and implies that the ectopic endometrial cells have migratory abilities [22]. Several risk factors including endocrine, genetic, biochemical, environmental, and immunological factors are effective in the initiation and progression of the disease [6,23]. These mechanisms might act in unison to cause endometriosis, but the main trophic factor in endometriosis is estrogen and estrogen exposure plays a crucial role in the development of the disease via estrogen receptors (ERs) [1].

The use of animal models in the study of endometriosis as well as clinical research have expanded our knowledge of pathogenesis and disease progression, highlighting the complexity of this disease that includes angiogenesis, inflammation, hormonal response and the associated signaling pathways. So, the aim of this review is focused on the role of ERs in the initiation and the progression of the disease. We also highlighted the latest advances of treatment strategies based on ERs modulation.

2. Levels of Estradiol and Estrogen Receptors in Endometriosis

It is well documented that endometriosis is intimately associated with steroid metabolism and associated pathways [1,24,25]. 17β-Estradiol (E2) is a key hormone for the growth and persistence of endometriotic tissue as well as the inflammation and pain associated with it. Estradiol reaches endometriosis by the circulation but it is mainly produced locally in the endometriotic tissue. This local estrogen accumulation has been considered to play an important role in the development and progression of endometriotic lesions by binding and activating ERs. This synthesis is upregulated in endometriotic tissue by altering the activities of enzymes involved in the biosynthesis and inactivation of estradiol [26,27]. In fact, endometriotic tissues have the ability to synthesize E2 de novo from cholesterol, because there is a high expression of two of the most important enzymes involved in the process of estrogen biosynthesis: aromatase (CYP19A1) and steroidogenic acute regulatory protein (StAR) (Figure 2). In contrast to endometriotic lesions, normal endometrium does not have the ability to synthesize estrogen due to the absence of these enzymes [27–29]. The enzyme aromatase is a member of the cytochrome P450 superfamily and is responsible for the last step in the synthesis of E2, i.e., the aromatization of androgens (androstenedione and testosterone) into estrogens (oestrone and E2, respectively). StAR facilitates the initial step of estrogen formation, the entry of cytosolic cholesterol into the mitochondrion. In addition, 17β-hydroxysteroid dehydrogenases (HSD17Bs) are involved in the formation of biologically active steroid hormones. The 17β-hydroxysteroid dehydrogenase 2 is implicated in the inactivation of E2 but the level and role of this enzyme are controversial [29,30].
The detailed mechanisms of the increase in ERβ remain unclear. The tissue- and cell-specific expression of a gene can be determined by DNA methylation. In fact, hypomethylation of the ERβ promoter region could be associated with the upregulation of the protein level in endometriotic tissues [40]. However, according to Maekawa et al., DNA methylation was not involved in the upregulation of ESR2 [46]. In addition, the downregulation of ESR1 in endometriosis could be caused
by an aberrant DNA methylation of a specific region of the gene called the tissue-dependent and differentially-methylated-region (T-DMR) [46]. It has been hypothesized that ESR2 suppressed ESR1 expression in endometriotic cells in culture by binding to classical and nonclassical cis-regulatory elements in specific promoters of the ESR1 [47]. DNA methylation seems to be an integral component of endometriosis, and according to Dyson et al. [48], the GATA family is a regulator of uterine physiology and aberrant DNA methylation in endometriotic cells correlates with a shift in GATA isoform expression that permits GATA6 expression in endometriosis instead of GATA2. This switch promotes the aberrant expression of many of the genes, including homeobox A10 (HOXA10), ERβ (ESR2), steroidogenic factor 1 (NR5A1), and aromatase (CYP19A1), which alter steroid signaling and responsiveness, and are critically involved in the disease development. In conclusion, epigenetic and genetic variations, such as post-translational modifications of ERs and coregulators, could alter their original function and become potent “drivers” of endometriosis progression [49].

3. The Role of ERs in Endometriosis

The molecular mechanisms regarding the specific contribution of each ER isoforms in the initiation and progression of the disease have been revealed in previous studies performed both in mouse models and in cells isolated from patients with endometriomas (summarized in Table 1). Beliard et al. reported a positive correlation between the proliferation and ER levels in normal and eutopic endometrium obtained from the peritoneum of women aged 26–40 years [50]. No correlation between apoptosis and estrogen receptor levels was found. However, the authors did not specify the antibody used and thus, did not differentiate between ERα and ERβ. Therefore, the ERα and ERβ knockout mice were used to surgically induce endometriosis-like lesion formations by injecting finely minced uterine tissue into the peritoneal cavity of the syngeneic host mice [51]. These mouse models revealed that both the ERα and the ERβ isoforms were required for the growth of endometriotic-like lesions [25,51]. However, the impact of estradiol which further increased the development of endometriosis-like lesions predominantly demonstrated the requirement of ERα for cell adhesion and proliferation, and for the neoangiogenesis that supports endometriosis-like lesion growth because the impact of an ERβ gene knockout was less than ERα gene deletion in the suppression of ectopic lesion growth [51]. More recently, the same mouse models were used to examine early disease development and its dependence on both E2 and ERα within 72 h of disease initiation. Using wild-type and ERα knockout mice as hosts or donors, the analysis of infiltrating cells after the initiation of endometriosis in mice, treated or not with E2, indicated a substantial infiltration of neutrophils and macrophages into the peritoneal cavity, irrespective of E2 or ERα status. However, IL-6 secretion was decreased 48 h after the disease initiation in αERKO to WT, as compared to WT to WT, providing evidence that E2/ERα/IL-6-mediated cross-talk played a partial role in increasing endometriosis lesion numbers [52].

Additionally, another study demonstrated that ERβ played a critical role in the development of endometriosis [53]. The modelization to surgically induce endometriosis lesions was slightly different, since the endometrial fragment isolated from the uterine tissue was sutured to the mesenteric membrane. They also used a mouse overexpressing ERβ and immortalized human endometrial epithelial cells injected into SCID mice. As a potential mechanism to evade immunosurveillance, they demonstrated that ERβ interacted with the apoptotic machinery in the cytoplasm to inhibit TNF-induced apoptosis, and with components of the cytoplasmic inflammasome to increase IL-1β that contributes to cell survival, to enhance the cellular proliferation, invasion and the adhesion activities of immortalized human endometrial cells. In these models, ERβ also contributed to the epithelial–mesenchymal transition [53]. ERβ overexpression could then increase endometriosis-associated infertility by preventing the decidualization response in the stromal compartment of eutopic endometrium [53].

Using a new endometrium-specific FLAG-tagged human ERβ overexpression mouse model, the ERβ-transcriptomic and cistromic analyses demonstrated that ERβ stimulated the gene expression associated with IL6/JAK/STAT inhibitory signaling in ectopic lesions to enhance progression [54]. A genome-wide comparative analysis of ERβ-binding and gene expression in human endometriosis
and endometrial tissues identified the Ras-like estrogen-regulated growth inhibitor (RERG) and serum and glucocorticoid-regulated kinase (SGK1) as key ERβ targets [44,55]. RERG induces ribosome biogenesis and the proliferation of primary endometriotic cells, thus integrating ERβ and prostaglandin E2 (PGE2). Signals at the RERG led to endometriotic cell proliferation [44]. Using siRNA knockdown of ERβ, the same group demonstrated that estradiol/ERβ also stimulated SGK1 expression and enzyme activity, leading to increased human endometriotic cell survival [55]. Finally, while steady state ERα:ERβ mRNA ratios were altered in stromal cells [56], the overexpression of ERβ in endometrial stromal cells significantly decreased ERα mRNA. This ERβ knock-down decreased the proliferation of endometrial stromal cells [47]. ERβ, acting as a suppressor of ERα, was then proposed to serve as a therapeutic target for endometriosis (see Part Treatments and Innovations).

In addition, the use of dominant negative mutants of estrogen receptor (DN-ER) genes, delivered to endometriosis cells (from ovarian endometriomas) via an adenovirus vector (Ad-DN-ER), abrogated the estrogen action on these cells and decreased cell proliferation, induced apoptosis and decreased cytokine production such as monocyte chemotactic protein-1, vascular endothelial growth factor, and interleukin-6 [57]. The invasion and migration of endometriosis eutopic stromal cells were regulated by estrogen/H19/miR-216a-5p/ACTA2 pathways. Specifically, the invasion and migration of these cells can be inhibited by the down regulation of H19 or ACTA2 [58].

One of the most characteristic pathogenetic features of endometriosis is the chronic pelvic inflammation. However, inflammation and estrogen production in endometriosis are linked by a positive feedback cycle in which the chronic overexpression of aromatase and COX2 supports the sustained production of estradiol and PGE2 in endometriotic tissue [59,60]. E2/ERβ stimulated PGE2 formation, whereas PGE2 stimulated estradiol synthesis [59,61]. Selective or nonselective COX inhibitors that disrupt PGE2 synthesis effectively reduced pelvic pain in endometriosis [62]. Moreover, in uterine microvascular endothelial cells, ERβ mediated estradiol-stimulated COX2 expression and PGE2 production [61].

New models such as three dimensional (3D) in vitro organoids have emerged to recapitulate the biological features of endometriosis. These in vitro organoids were initially developed from healthy mouse and human endometrium, expanded long-term and copied the phenotype of the epithelium in terms of response to hormones, including increased cell proliferation under estrogen and maturation upon progesterone [63,64]. Very recently, long-term expandable patient-derived organoids were prepared from endometrial disorders, including endometriosis and endometrial cancer [64,65]. They exhibited ERα and progesterone receptor (PR) expression as in the initial endometriotic tissue. These organoids were further transplanted under the kidney capsule or into the peritoneum of NOD-SCID mice previously implanted with an estradiol pellet and were able to generate implants expressing the ER+ and PR+ lesions [65]. The expression of ERβ protein was not evaluated, and the large-scale transcriptomic analysis performed between the healthy endometrium and eutopic, or ectopic lesions did not reveal a differential expression of the ESR2 gene, encoding ERβ, questioning the previous data showing the upregulation of ERβ [65].

Altogether, it appears that ERβ and ERα act in a variety of ways to promote the proliferation of endometrial cells and tissue-invasion activity in endometriosis sites to establish ectopic lesions, with potentially a central role for ERβ in the development and pathophysiology of endometriosis (Figure 3). The overproduction of estradiol in endometriosis drives ERβ signaling to support endometriotic tissue survival and inflammation. Additionally, ERβ may have estradiol-independent pathologic actions.
Table 1. Summary of the different studies on ERα and ERβ expression in endometriosis. IHC= Immunohistochemistry; IP= Immunoprecipitation. The “underline” is to emphasize the species: Human, mouse or rat and to also emphasize some cell types such as stromal or endothelial cells

| Studies                        | ER or ERβ | Procedures                              | Models                                      | Results                                                                 |
|-------------------------------|-----------|-----------------------------------------|---------------------------------------------|------------------------------------------------------------------------|
| Enmark et al., 1997 [37]      | ERβ/ERα   | mRNA by RT-PCR                          | Rat tissues                                | Expression ERα was significantly higher than that of ERβ in normal endometrium. |
| Brandenberger et al., 1999 [56]| ERβ/ERα   | mRNA by RT-PCR  
Southern blot  
Ligand-binding assays    | Human normal endometrial and endometriosis-derived stromal cells | Ratio of ERα/ERβ mRNA in stromal cells were decreased in endometriosis as compared to normal endometrium |
| Fujimoto et al., 1999 [43]    | ERβ and ERα | mRNA by RT-PCR  
IHC (Anti-ERα (MC-20) et ERβ – L-20)  
Southern blot    | Human ovarian endometrioma  
Normal endometrium | In normal endometrium, ERα mRNA were expressed at a higher level than those of ERβ. However, ERβ mRNA expression was higher and over a much greater range in ovarian endometrioma than normal endometrium while ERα expression was lower and more random. |
| Matsuzaki et al., 2001 [39]   | ERβ and ERα | mRNA  
RT-PCR assay  
TaqMan RT-PCR  
Nonradioactive in situ hybridization    | Human ovarian endometrioma  
Normal endometrium | The predominant expression of ERs in both glandular epithelial and stromal cells might have been essential for the development and growth of peritoneal and ovarian endometriosis. The expression of ER was modulated according to the menstrual cycle |
| Beliard et al., 2004 [50]     | -No differentiation between ERα and ERβ | Nuclear staining  
IHC  
Antibodies used not specified    | Human endometriotic tissues (peritoneum) | -No correlation between apoptosis and estrogen receptor levels was found  
-A lower amount of steroid receptor was found in endometriotic tissues without cyclic modulation compared with the eutopic endometrium |
| Tamura et al., 2004 [61]      | ERβ and ERα | mRNA and protein  
RT-PCR  
Western Blot    | Human uterine microvascular endothelial cells | In uterine microvascular endothelial cells, ERβ mediated estradiol-stimulated COX2 expression and PGE2 production |
| Xue et al., 2007 [40]         | ERβ and ERα | mRNA by RT-PCR  
Western blot    | Human endometrial and endometriotic stromal cells from ovarian endometriomas | -mRNA (34-fold) and protein levels of ERβ were higher in endometriotic stromal cells due to hypomethylation of a CpG island  
whereas level of ERα was lower in paired endometriotic versus endometrial stromal cells |
| Bukulmez et al., 2008 [42]    | ERβ/ERα   | mRNA and protein  
IHC  
Histology  
qRT-PCR  
Western blot    | Human endometriotic tissues  
Normal endometrium | Expression ERβ is significantly higher than that of ERα in ectopic endometrium |
| Studies                        | ER or ERβ | Procedures            | Models                                      | Results                                                                                                                   |
|-------------------------------|-----------|-----------------------|---------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| Trukhacheva et al., 2009      | ERβ and ERα | Si-RNA knockdown RT-PCR IP Western Blot | Human ovarian endometrioma                 | Overexpression of ERβ in endometriotic stromal cells significantly decreased ERα mRNA and protein levels, and ERβ knock-down significantly decreased proliferation of endometriotic stromal cells |
| Cheng et al., 2011            | ERβ       | mRNA by RT-PCR IHC   | Mouse: They transplanted steroid-manipulated, menstrual-like endometrium from K-ras(G12V+)/+Ah-Cre(++)/ROSA26R-LacZ(++)/mice into gonad-intact immunocompetent wild-type mice | Elevated levels of ERβ existed in both nuclear and cytoplasmic locations in this mouse model of endometriosis          |
| Burns et al., 2012            | ERβ/ERα    | mRNA by RT-PCR IHC   | Mouse: Uterus samples injected in peritoneal cavity | ERβ gene knockout was less than ERα gene deletion in the suppression of ectopic lesion growth                           |
| Pellegrini et al., 2012       | ERβ and ERα | mRNA byRT-PCR IHC   | Human endometrium with or without endometriosis | mRNA of ERβ and ERα were upregulated in the eutopic endometrial tissue of patients with endometriosis ERβ and ERα as well as c-myc, cyclin D1 mRNA expression levels were increased in ectopic tissue in comparison with both normal and eutopic endometrium |
| Monsivais et al., 2014        | ERβ       | Genome-wide comparative analysis of ERβ binding and gene expression   | Human endometriosis and endometrial tissues | Ras-like estrogen-regulated growth inhibitor (RERG) and serum and glucocorticoid-regulated kinase (SGK1) are identified as key ERβ targets |
| Han and al., 2014 (Review)    | ERβ and ERα | Gene expression microarray data | Human endometriotic tissues | Aberrant levels of nuclear receptors and nuclear receptors co-regulators in ectopic endometriotic lesions were associated with the progression of endometriosis |
| Zhao et al., 2015             | ERβ/ERα    | mRNA by RT-PCR IHC   | Mouse: Immunocompetent mice ERβKO and ERαKO Human endometriotic stromal cells in culture | Both the ERα and the ERβ isoforms were required for the growth of endometriotic-like lesions |

Table 1. Cont.
Table 1. Cont.

| Studies              | ER or ERβ | Procedures          | Models                                      | Results                                                                 |
|----------------------|-----------|---------------------|---------------------------------------------|-------------------------------------------------------------------------|
| Han et al., 2015     | ERβ       | -IHC                | They used mouse overexpressing ERβ and immortalized human endometrial epithelial cells injected in SCID mice | -ERβ also contributed to the epithelial-mesenchymal transition; ERβ overexpression could then increase endometriosis-associated infertility -ERβ played a critical role in endometriosis development, interacted with the apoptotic machinery in the cytoplasm to inhibit TNF-induced apoptosis and with the components of the cytoplasmic inflammasome to increase IL-1β |
| Monsivais et al., 2016 | ERβ       | siRNA knockdown of ERβ RT-PCR IHC Western Blot | Human ovarian endometriosis and normal endometrial tissues | Estradiol/ERβ also stimulated SGK1 expression and enzyme activity, leading to increased human endometriotic cell survival |
| Burns et al., 2018   | ERα       | mRNA by RT-PCR Flow cytometry Cytokine production | Mouse (WT, αERKO) | E2/ERα/IL-6-mediated cross-talk played a partial role in increasing endometriosis lesion numbers |
| Han et al., 2019     | ERβ       | ERβ-transcriptomic and cistromic analyses | New endometrium-specific FLAG-tagged human ERβ overexpression mouse model | ERβ stimulated gene expression associated with IL6/JAK/stat inhibitory signaling in ectopic lesions to enhance progression |
Different methodologies and different endometriotic lesions (ovarian vs. peritoneal) have been demonstrated to be relatively higher than in the normal endometrium and this induction was mediated by estrogen, stress and inflammation [31]. It can also regulate the rapid activation of the phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) pathways. GPER expression in endometriotic tissue has been demonstrated to be relatively higher than in the normal endometrium and this induction was mediated by estrogen, stress and inflammation [67–69]. GPER is maximally expressed during the proliferative phase. In follicles of ovaries affected by endometriosis, GPER was found to be down-regulated, further supporting a role for GPER in folliculogenesis [69].

### Figure 3. Molecular pathways of ER regulation in endometriosis lesions.

(A). Overexpression of ERβ in the stromal endometriotic cells inhibits the TNFα-mediated apoptosis, acts as a suppressor of ERα, induces interleukin-1, co-stimulates Ras-related estrogen-regulated growth inhibitor (RERG) and serum and glucocorticoid-regulated kinase (SGK1) as key ERβ targets with co-stimulating prostaglandin E2 (PGE2) under the action of estradiol. (B). De novo increase of 17β-Estradiol (E2) in endometriosis lesions affecting the ratio of ERα and ERβ, impacting the inflammation and expression of some target genes such as Greb-1 and c-Myc that results in endometriosis progression [2,27].

However, we must remain cautious about the role of ERβ in endometriosis. Andersson et al. questioned the expression of ERβ in several tissues due to the absence of validation of the anti-ERβ antibody used [66]. Moreover, the comparison of results obtained in different studies was hampered by the use of different methodologies and different endometriotic lesions (ovarian vs. peritoneal endometriosis).

Estrogens can also exert its effects through nongenomic signaling via cell membrane ERs. GPER (a seven-pass transmembrane G Protein-coupled Estrogen Receptor), also known as G protein-coupled receptor 30 (GPR30), has been identified as a novel receptor with binding ability to E2 in cell membranes, endoplasmic reticulum and the Golgi apparatus, and can trigger rapid estrogen non-genomic signaling independent of ERα and ERβ [31]. It can also regulate the rapid activation of the phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) pathways. GPER expression in endometriotic tissues has been demonstrated to be relatively higher than in the normal endometrium and this induction was mediated by estrogen, stress and inflammation [67–69]. GPER is maximally expressed during the proliferative phase. In follicles of ovaries affected by endometriosis, GPER was found to be down-regulated, further supporting a role for GPER in folliculogenesis [69].

### 4. Treatments and Innovations in Clinical Management Related to ERs

The goals of medical therapy for endometriosis are pain control, improvement of the quality of life, prevention of disease recurrence, fertility preservation and the reduction of operative intervention [70]. Estrogen is the most hierarchically upstream and potent stimulus of survival and inflammation in eutopic and ectopic endometrial tissues. Thus, treatments for symptomatic endometriosis inhibiting ovarian estradiol production (contraceptive steroids, GnRH agonists, progestins, and aromatase inhibitors) would give limited benefit to women with autonomous endometriotic estradiol production [5]. In addition, the use of estrogen receptor ligands, inhibitors, and agonists also support the role of these receptors in endometriosis [24].

The potential of ERβ as a therapeutic target in endometriosis has been recognized. ERβ-selective compounds that act as estradiol antagonists in endometriotic tissue would be potential therapeutics. One study showed that a selective ERβ agonist (ERB-041) achieved lesion size regression compared with a vehicle in athymic nude mice implanted with fragments of normal human endometrium [71].
Another study treated surgically-induced endometriosis lesions in C57BL/6J mice with an ERβ-selective antagonist, such as PHTPP, to suppress ectopic lesion growth [53]. This discrepancy between the efficacy of an ERβ agonist or an ERβ antagonist can potentially be explained by difference in ERβ expression between normal and ectopic endometrial lesions, respectively in each study.

A link between ERβ, TNF and IL-1β has been highlighted in endometriosis lesions and would have a predominant role in endometriosis progression. Moreover, the blockage of TNF action using systemically administered recombinant TNF receptor type-1 or a monoclonal antibody against TNF prevented the establishment of endometriosis, or reduced the lesion size in a baboon model of endometriosis [72]. The SRC-1 isoform/ERβ complex played an essential role in the early stages of endometriosis pathogenesis and could be a next-generation endometriosis therapeutic target with reduced side effects compared to the current endometriosis treatment, because ERβ and the SRC-1 isoform have little expression in the eutopic endometrium [53]. In addition, estradiol induced COX2 via ERβ in endometriosis. The disruption of PGE2 synthesis via selective or nonselective COX inhibitors effectively reduced pelvic pain in endometriosis [73]. The two ER ligands (one highly selective ERβ ligand, the chloroindazole (CLI) and the ERα antagonist, oxabicycloheptene sulfonate (OBHS)) have strong ER-dependent anti-inflammatory effects on endometriosis lesions in vivo in a suture mouse model of endometriosis and in vitro, with primary human endometriotic stromal cells [25]. These ligands displayed potent antiestrogenic and anti-inflammatory activities mediated via the ERs in endometriotic cells.

Selective estrogen receptor modulators (SERMs) are synthetic molecules which bind to ERs and act either as antagonists or agonists, depending on the tissue type. The majority of findings were obtained in animal models and the effectiveness of SERMs in human endometriosis is still to be evaluated. In experimental models, SERMs showed a direct effect on endometrial blood vessels and suppressed endometrial prostaglandin production without the systemic effects of estrogen deprivation. Raloxifene, used for the treatment of postmenopausal osteoporosis, was tested in a rat model of endometriosis and was shown to have an estrogen-antagonist effect on the rat uterine tissue, producing implants' regression [74]. In animal models, raloxifene showed comparable benefits with anastrozole in reducing the size of lesion [75]. In a randomized clinical trial, raloxifene statistically significantly shortened the time to the return of chronic pelvic pain [76]. Newer generation SERM, bazedoxifen, was being extensively studied for endometriosis therapy. In a mouse model, bazedoxifen, alone or combined with conjugated estrogen, reduced estrogen receptor expression in the endometrium and the size of endometriotic lesions [77,78]. Recently, Flores et al. have evaluated the effects of bazedoxifene paired with conjugated estrogens on reproductive hormones and uterine/ovarian appearance in premenopausal women. After one daily administration of bazedoxifene/conjugated estrogens for 12 weeks, all subjects demonstrated an LH surge without endometrial alterations or abnormal ovarian folliculogenesis [79]. Khine et al. evaluated the effects of SR-16234 on murine endometriosis-like lesions [80]. SR-16234 is a SERM which was reported to have ERα-antagonist activity with a weak partially agonist activity to the ERβ receptor. They demonstrated that this SERM suppressed the growth and the expression of inflammation-associated genes in endometriosis-like lesions without inducing endometrial growth.

Moreover, estrogens can activate some non-genomic pathways of ERs, that activate rapid signaling between seconds or minutes, forming complexes with G proteins, growth factor receptors (IGF-IR, EGFR...); or non-receptor tyrosine kinase (e.g., SRC) that increase levels of nitric oxide, MAPK/ERK or PI3K/AKT kinases, and reactive oxygen species (ROS). These observations have prompted several groups to target these pathways, both in vitro and in vivo, testing the therapeutic potential of specific inhibitors of the MAPK/ERK, PI3K/AKT pathways [81].

Aromatase inhibitors offer an innovative approach to the treatment of this disorder, and these inhibitors, alone or in combination with more standard treatments, could be successful in eradicating treatment refractory endometriotic implants and improving pain symptoms when other medical therapies, such as GnRH agonists, have failed [1]. In premenopausal women, an aromatase inhibitor
alone may induce ovarian folliculogenesis, and thus aromatase inhibitors are combined with a progestin, a combined oral contraceptive, or a GnRH agonist [82]. These combinations reduced visible lesions and pelvic pain refractory to other available medical and conservative surgical treatments [83,84]. In postmenopausal situations and in particular in cases of lesions that cannot be resected surgically, aromatase inhibitors are the treatment of choice [22,85].

Progesterone and progestins are also used in the management of symptomatic endometriosis. Selective progesterone receptor modulators (SPRMs) with primarily antiprogestogenic effects include mifepristone (RU486), asoprisnil, and ulipristal acetate [86]. They have demonstrated benefits in reducing pain and suppressing the extent of endometriotic lesions through several mechanisms: inducing anovulation, reducing the expression of aromatase, reducing the expression and enzyme activity of 17β-HSD1 (hydroxysteroid dehydrogenase, which catalyzes the conversion of estrone to estradiol), altering ERs, inhibiting angiogenesis and decreasing the expression of matrix metalloproteinases needed for the growth of the endometriotic implant [87]. They are often called “mini-pill”, and it appears that this treatment should be the first-line therapy since they can eliminate pain and induce amenorrhea, improve the quality of life and reduce the size of endometriosis [88].

Apart from all these hormonal treatments, numerous immune-modulators or anti-angiogenic agents are currently being tested and developed [88,89] while the function of non-coding RNAs in endometrial physiology and physiopathology are also being discussed [90].

5. Conclusions

High estrogen production is a consistently observed feature of endometriosis and this review highlighted the fact that estrogen and its receptors play a key role in the pathophysiology of endometriosis. Targeting the local production of E2 might be a potential therapeutic strategy to block the development of endometrial disease. However, many questions remain opened concerning the specific role of ERα, which might be involved during the phase of initiation of the disease while it is necessary to confirm the upregulation of ERβ according to the anatomical site of the lesion after validation of the antibodies used. Moreover, although it is well known that endometriosis is a chronic inflammatory disease, and although some roles of ERα and ERβ have been mentioned in the inflammatory response, the impact of E2 and ERα/ERβ on immunity for the initiation and development of endometrial disease remain totally unresolved. The study of these new ER mechanisms with better diagnosis allowing to discriminate between a large variety of phenotypes should generate new ideas for the next generation of therapies for endometriosis that are clearly needed. They will be based on the development and improvement of current therapies, including oral GnRH antagonists, SERMs or SPRMs that will relieve pain symptoms, inflammation without suppressing ovulation. In this context, finding therapies that target both endocrine and inflammatory pathways might be of interest to better cure the origin of the disease.

Author Contributions: Conceptualization, E.C., M.-C.V., J.-F.A., and F.L.; validation, E.C., J.-F.A., and F.L.; resources, J.-F.A. and F.L.; writing—original draft preparation, E.C., M.-C.V., C.V., E.N., A.W., K.V., E.B., C.F., J.-F.A., F.L.; writing—review and editing, E.C., M.-C.V., P.L., C.F., J.-F.A., F.L.; visualization, M.R.; supervision, E.C., J.-F.A. and F.L.; funding acquisition, E.C., J.-F.A. and F.L. All authors have read and agreed to the published version of the manuscript.

Funding: The work at I2MC-INSERM U1048 is supported by: Institut National de la Santé et de la Recherche Médicale, Université et CHU de Toulouse, Faculté de Médecine Toulouse-Rangueil, Fondation pour la Recherche Médicale and the « Association française de lutte contre l’endométriose » (Endofrance, Grant to E.C.)

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
References

1. Giudice, L.C.; Kao, L.C. Endometriosis. *Lancet* 2004, 364, 1789–1799. [CrossRef]
2. Bulun, S.E.; Yilmaz, B.D.; Sison, C.; Miyazaki, K.; Bernardi, L.; Liu, S.; Kohlmeier, A.; Yin, P.; Milad, M.; Wei, J. Endometriosis. *Endocr. Rev.* 2019, 40, 1048–1079. [CrossRef]
3. Zondervan, K.T.; Becker, C.M.; Koga, K.; Missmer, S.A.; Taylor, R.N.; Vigano, P. Endometriosis. *Nat. Rev. Dis. Prim.* 2018, 4, 9. [CrossRef] [PubMed]
4. Chantaltat, E.; Vidal, F.; Legueuvaque, P.; Lepage, B.; Lambaudie, E.; Hebert, T.; Motton, S. Para-aortic workup in locally advanced cervical cancer: Heterogeneity is still the rule. Results from a retrospective multicenter study. *Arch. Gynecol. Obstet.* 2016, 293, 1081–1086. [CrossRef] [PubMed]
5. Bulun, S.E. Endometriosis. *New Engl. J. Med.* 2009, 360, 268–279. [CrossRef] [PubMed]
6. Chapron, C.; Marcellin, L.; Borghese, B.; Santulli, P. Rethinking mechanisms, diagnosis and management of endometriosis. *Nat. Rev. Endocrinol.* 2019, 15, 666–682. [CrossRef]
7. Prescott, J.; Farland, L.V.; Tobias, D.K.; Gaskins, A.J.; Spiegelman, D.; Chavarro, J.E.; Rich-Edwards, J.W.; Barbieri, R.L.; Missmer, S.A. A prospective cohort study of endometriosis and subsequent risk of infertility. *Hum. Reprod.* 2016, 31, 1475–1482. [CrossRef]
8. de Ziegler, D.; Borghese, B.; Chapron, C. Endometriosis and infertility: Pathophysiology and management. *Lancet* 2010, 376, 730–738. [CrossRef]
9. Pluchino, N.; Wenger, J.M.; Petignat, P.; Tal, R.; Bolmont, M.; Taylor, H.S.; Bianchi-Demicheli, F. Sexual function in endometriosis patients and their partners: Effect of the disease and consequences of treatment. *Hum. Reprod. Update* 2016, 22, 762–774. [CrossRef]
10. Nnoaham, K.E.; Hummelshoj, L.; Webster, P.; d’Hooghe, T.; de Cicco Nardone, F.; de Cicco Nardone, C.; Jenkinson, C.; Kennedy, S.H.; Zondervan, K.T.; World Endometriosis Research Foundation Global Study of Women’s Health Consortium. Impact of endometriosis on quality of life and work productivity: A multicenter study across ten countries. *Fertil. Steril.* 2011, 96, 366–373 e368. [CrossRef]
11. Canis, M.; Donnez, J.G.; Guizick, D.S.; Halme, J.K.; Rock, J.A.; Schenken, R.S.; Vernon, M.W. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. *Fertil. Steril.* 1997, 67, 817–821. [CrossRef]
12. Wang, W.; Li, R.; Fang, T.; Huang, L.; Ouyang, N.; Wang, L.; Zhang, Q.; Yang, D. Endometriosis fertility index score maybe more accurate for predicting the outcomes of in vitro fertilisation than r-APFS classification in women with endometriosis. *Reprod. Biol. Endocrinol.* 2013, 11, 112. [CrossRef] [PubMed]
13. Foti, P.V.; Farina, R.; Palmucci, S.; Vizzini, I.A.A.; Libertini, N.; Coronella, M.; Spadola, S.; Caltabiano, R.; Iraci, M.; Basile, A.; et al. Endometriosis: Clinical features, MR imaging findings and pathologic correlation. *Insights Imaging* 2018, 9, 149–172. [CrossRef] [PubMed]
14. Facchin, F.; Barbara, G.; Saita, E.; Mosconi, P.; Roberto, A.; Fedele, L.; Vercellini, P. Impact of endometriosis on quality of life and mental health: Pelvic pain makes the difference. *J. Psychosom. Obstet. Gynaecol.* 2015, 36, 135–141. [CrossRef] [PubMed]
15. Marki, G.; Bokor, A.; Rigo, J.; Rigo, A. Physical pain and emotion regulation as the main predictive factors of health-related quality of life in women living with endometriosis. *Hum. Reprod.* 2017, 32, 1432–1438. [CrossRef] [PubMed]
16. Minelli, L.; Fanfani, F.; Fagotti, A.; Ruffo, G.; Ceccaroni, M.; Mereu, L.; Landi, S.; Pomin, P.; Scambia, G. Laparoscopic colorectal resection for bowel endometriosis: Feasibility, complications, and clinical outcome. *Arch. Surg.* 2009, 144, 234–239. [CrossRef]
17. Guo, S.W. Recurrence of endometriosis and its control. *Hum. Reprod. Update* 2009, 15, 441–461. [CrossRef]
18. Millochau, J.C.; Abo, C.; Darwish, B.; Huet, E.; Dietrich, G.; Roman, H. Continuous Amenorrhea May Be Insufficient to Stop the Progression of Colorectal Endometriosis. *J. Minim. Invas. Gynecol.* 2016, 23, 839–842. [CrossRef]
19. Sampson, J.A. Metastatic or Embolic Endometriosis, due to the Menstrual Dissemination of Endometrial Tissue into the Venous Circulation. *Am. J. Pathol.* 1927, 3, 93–110.43.
20. Khan, A.W.; Craig, M.; Jarmulowicz, M.; Davidson, B.R. Liver tumours due to endometriosis and endometrial stromal sarcoma. *HPB Offic. J. Int. Hepato Pancreat. Biliary Assoc.* 2002, 4, 43–45. [CrossRef]
21. Koninckx, P.R.; Barlow, D.; Kennedy, S. Implantation versus infiltration: The Sampson versus the endometriotic disease theory. *Gynecol. Obstet. Invest.* 1999, 47, 3–9. [CrossRef] [PubMed]
22. Eychenne, C.; Suc, B.; Delchier, M.C.; Vidal, F.; Rimailho, J.; Illac, C.; Breibach, F.; Vaysse, C.; Chantalat, E. Hepatic pedicle endometriosis: Case report and review of the literature. J. Obstet. Gynecol. Res. 2019, 45, 2121–2127. [CrossRef] [PubMed]

23. Ahn, S.H.; Monsanto, S.P.; Miller, C.; Singh, S.S.; Thomas, R.; Tayade, C. Pathophysiology and Immune Dysfunction in Endometriosis. BioMed Res. Int. 2015, 2015, 795976. [CrossRef]

24. Greene, A.D.; Lang, S.A.; Kendziorski, J.A.; Sroga-Rios, J.M.; Herzog, T.J.; Burns, K.A. Endometriosis: Where are we and where are we going? Reproduction 2016, 152, R63–R78. [CrossRef] [PubMed]

25. Zhao, Y.; Gong, P.; Chen, Y.; Nwachukwu, J.C.; Srivivasan, S.; Ko, C.; Bagchi, M.K.; Taylor, R.N.; Korach, K.S.; Nettles, K.W.; et al. Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. Sci. Transl. Med. 2015, 7. [CrossRef] [PubMed]

26. Bulun, S.E.; Monsavais, D.; Pavone, M.E.; Dyson, M.; Xue, Q.; Attar, E.; Tokunaga, H.; Su, E.J. Role of estrogen receptor-beta in endometriosis. Semin. Reprod. Med. 2012, 30, 39–45. [CrossRef]

27. Tang, Z.R.; Zhang, R.; Lian, Z.X.; Deng, S.L.; Yu, K. Estrogen-Receptor Expression and Function in Female Reproductive Disease. Cells 2019, 8, 1123. [CrossRef]

28. Zeitoun, K.M.; Bulun, S.E. Aromatase: A key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil. Steril. 1999, 72, 961–969. [CrossRef]

29. Mori, T.; Ito, F.; Koshiha, A.; Kataoka, H.; Takaoka, O.; Okimura, H.; Khan, K.N.; Kitawaki, J. Local estrogen formation and its regulation in endometriosis. Reprod. Med. Biol. 2019, 18, 305–311. [CrossRef]

30. Zeitoun, K.; Takayama, K.; Sasano, H.; Suzuki, T.; Moughrabi, N.; Andersson, S.; Johns, A.; Meng, L.; Putman, M.; Carr, B.; et al. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: Failure to metabolize 17beta-estradiol. J. Clin. Endocrinol. Metab. 1998, 83, 4474–4480. [CrossRef]

31. Arnal, J.F.; Lenfant, F.; Metivier, R.; Flouriot, G.; Henrion, D.; Adlanmerini, M.; Fontaine, C.; Gourdy, P.; Chambon, P.; Katzenellenbogen, B.; et al. Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications. Physiol. Rev. 2017, 97, 1045–1087. [CrossRef] [PubMed]

32. Ascenzi, P.; Bocedi, A.; Marino, M. Structure-function relationship of estrogen receptor alpha and beta: Impact on human health. Mol. Aspects Med. 2006, 27, 299–402. [CrossRef] [PubMed]

33. Sagae, S.; Monk, B.J.; Pujade-Lauraine, E.; Gaffney, D.K.; Narayan, K.; Ryu, S.Y.; McCormack, M.; Plante, M.; Casado, A.; Reuss, A.; et al. Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future. Int. J. Gynecol. Cancer 2016, 26, 199–207. [CrossRef] [PubMed]

34. Reslan, O.M.; Khalil, R.A. Vascular effects of estrogenic menopausal hormone therapy. Rev. Recent Clin. Trials 2012, 7, 47–70. [CrossRef]

35. Feldman, R.D.; Limbird, L.E. GPER (GPR30): A Nongenomic Receptor (GPCR) for Steroid Hormones with Implications for Cardiovascular Disease and Cancer. Ann. Rev. Pharmacol. Toxicol. 2017, 57, 567–584. [CrossRef]

36. Muka, T.; Vargas, K.G.; Jaspers, L.; Wen, K.X.; Dhana, K.; Vitezova, A.; Nano, J.; Brahaimaj, A.; Colpani, V.; Bano, A.; et al. Estrogen receptor beta actions in the female cardiovascular system: A systematic review of animal and human studies. Maturitas 2016, 86, 28–43. [CrossRef]

37. Enmark, E.; Pelto-Huikko, M.; Grandien, K.; Lagercrantz, S.; Lagercrantz, J.; Fried, G.; Nordenskjold, M.; Gustafsson, J.A. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrinol. Metab. 1997, 82, 4258–4265. [CrossRef]

38. Pellegrini, C.; Gori, I.; Achtari, C.; Hornung, D.; Chardonnens, E.; Wunder, D.; Fiche, M.; Canny, G.O. The expression of estrogen receptors as well as GREB1, c-MYC, and cyclin D1, estrogen-regulated genes implicated in proliferation, is increased in peritoneal endometriosis. Reprod. Sci. 2012, 19, 1200–1208. [CrossRef]

39. Matsuzaki, S.; Murakami, T.; Uehara, S.; Canis, M.; Sasano, H.; Okamura, K. Expression of estrogen receptor alpha and beta in peritoneal and ovarian endometriosis. Fertil. Steril. 2001, 75, 1198–1205. [CrossRef]

40. Xue, Q.; Lin, Z.; Cheng, Y.H.; Huang, C.C.; Marsh, E.; Yin, P.; Milad, M.P.; Confino, E.; Reierstad, S.; Innes, J.; et al. Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol. Reprod. 2007, 77, 681–687. [CrossRef]

41. Hewitt, S.C.; Harrell, J.C.; Korach, K.S. Lessons in estrogen biology from knockout and transgenic animals. Annu. Rev. Physiol. 2005, 67, 285–308. [CrossRef] [PubMed]

42. Bukulmez, O.; Hardy, D.B.; Carr, B.R.; Word, R.A.; Mendelson, C.R. Inflammatory status influences aromatase and steroid receptor expression in endometriosis. Endocrinology 2008, 149, 1190–1204. [CrossRef] [PubMed]
43. Fujimoto, J.; Hirose, R.; Sakaguchi, H.; Tamaya, T. Expression of oestrogen receptor-alpha and -beta in ovarian endometrioma. *Mol. Hum. Reprod.* 1999, 5, 742–747. [CrossRef] [PubMed]

44. Monsivais, D.; Dyson, M.T.; Yin, P.; Coon, J.S.; Navarro, A.; Feng, G.; Malpaimi, S.S.; Ono, M.; Ercan, C.M.; Wei, J.J.; et al. ERbeta- and prostaglandin E2-regulated pathways integrate cell proliferation via Ras-like and estrogen-regulated growth inhibitor in endometriosis. *Mol. Endocrinol.* 2014, 28, 1304–1315. [CrossRef]

45. Cheng, C.W.; Licence, D.; Cook, E.; Luo, F.; Arends, M.J.; Smith, S.K.; Print, C.G.; Charnock-Jones, D.S. Activation of mutated K-ras in donor endometrial epithelium and stroma promotes lesion growth in an intact immunocompetent murine model of endometriosis. *J. Pathol.* 2011, 224, 261–269. [CrossRef]

46. Maekawa, R.; Mihara, Y.; Sato, S.; Okada, M.; Tamura, I.; Shinagawa, M.; Shirafuta, Y.; Takagi, H.; Taketani, T.; Tamura, H.; et al. Aberrant DNA methylation suppresses expression of estrogen receptor 1 (ESR1) in ovarian endometrioma. *J. Ovar. Res.* 2019, 12, 14. [CrossRef]

47. Trukhacheva, E.; Lin, Z.; Reierstad, S.; Cheng, Y.H.; Milad, M.; Bulun, S.E. Estrogen receptor (ER) beta regulates ERalpha expression in stromal cells derived from ovarian endometriosis. *J. Clin. Endocrinol. Metab.* 2009, 94, 615–622. [CrossRef]

48. Dyson, M.T.; Roqueiro, D.; Monsivais, D.; Ercan, C.M.; Pavone, M.E.; Brooks, D.C.; Kakinuma, T.; Ono, M.; Jafari, N.; Dai, Y.; et al. Genome-wide DNA methylation analysis predicts an epigenetic switch for GATA factor expression in endometriosis. *PLoS Genet.* 2014, 10, e1004158. [CrossRef]

49. Han, S.J.; O’Malley, B.W. The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis. *Hum. Reprod. Update* 2014, 20, 467–484. [CrossRef]

50. Beliard, A.; Noel, A.; Foidart, J.M. Reduction of apoptosis and proliferation in endometriosis. *Fertil. Steril.* 2004, 82, 80–85. [CrossRef]

51. Burns, K.A.; Rodriguez, K.F.; Hewitt, S.C.; Janardhan, K.S.; Young, S.L.; Korach, K.S. Role of estrogen receptor signaling required for endometriosis-like lesion establishment in a mouse model. *Endocrinology* 2012, 153, 3960–3971. [CrossRef] [PubMed]

52. Burns, K.A.; Thomas, S.Y.; Hamilton, K.J.; Young, S.L.; Cook, D.N.; Korach, K.S. Early Endometriosis in Females Is Directed by Immune-Mediated Estrogen Receptor alpha and IL-6 Cross-Talk. *Endocrinology* 2018, 159, 103–118. [CrossRef] [PubMed]

53. Han, S.J.; Jung, S.Y.; Wu, S.P.; Hawkins, S.M.; Park, M.J.; Kyoo, S.; Qin, J.; Lydon, J.P.; Tsai, S.Y.; Tsai, M.J.; et al. Estrogen Receptor beta Modulates Apoptosis Complexes and the Inflammasome to Drive the Pathogenesis of Endometriosis. *Cell* 2015, 163, 960–974. [CrossRef] [PubMed]

54. Han, S.J.; Lee, J.E.; Cho, Y.J.; Park, M.J.; O’Malley, B.W. Genomic Function of Estrogen Receptor beta in Endometriosis. *Endocrinology* 2019, 160, 2495–2516. [CrossRef] [PubMed]

55. Monsivais, D.; Dyson, M.T.; Yin, P.; Navarro, A.; Coon, J.S.T.; Pavone, M.E.; Bulun, S.E. Estrogen receptor beta regulates endometriotic cell survival through serum and glucocorticoid-regulated kinase activation. *Fertil. Steril.* 2016, 105, 1266–1273. [CrossRef] [PubMed]

56. Brandenberger, A.W.; Lebovic, D.I.; Tee, M.K.; Ryan, I.P.; Tseng, J.F.; Jaffe, R.B.; Taylor, R.N. Oestrogen receptor (ER)-alpha and ER-beta isoforms in normal endometrial and endometriosis-derived stromal cells. *Mol. Hum. Reprod.* 1999, 5, 651–655. [CrossRef]

57. Othman, E.E.; Salama, S.; Ismail, N.; Al-Hendy, A. Toward gene therapy of endometriosis: Adenovirus-mediated delivery of dominant negative estrogen receptor genes inhibits cell proliferation, reduces cytokine production, and induces apoptosis of endometriotic cells. *Fertil. Steril.* 2007, 88, 462–471. [CrossRef]

58. Xu, Z.; Zhang, L.; Yu, Q.; Zhang, Y.; Yan, L.; Chen, Z.J. The estrogen-regulated IncRNA H19/miR-216a-5p axis alters stromal cell invasion and migration via ACTA2 in endometriosis. *Mol. Hum. Reprod.* 2019, 25, 550–561. [CrossRef]

59. Noble, L.S.; Takayama, K.; Zeitoun, K.M.; Putman, J.M.; Johns, D.A.; Hinshelwood, M.M.; Agarwal, V.R.; Zhao, Y.; Carr, B.R.; Bulun, S.E. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. *J. Clin. Endocrinol. Metab.* 1997, 82, 600–606. [CrossRef]

60. Sun, H.S.; Hsiao, K.Y.; Hsu, C.C.; Wu, M.H.; Tsai, S.J. Transactivation of steroidogenic acute regulatory protein in human endometriotic stromal cells is mediated by the prostaglandin EP2 receptor. *Endocrinology* 2003, 144, 3934–3942. [CrossRef]
61. Tamura, M.; Deb, S.; Sebastian, S.; Okamura, K.; Bulun, S.E. Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. *Fertil. Steril.* **2004**, *81*, 1351–1356. [CrossRef] [PubMed]

62. Daniels, J.; Gray, R.; Hills, R.K.; Latthe, P.; Buckley, L.; Gupta, J.; Selman, T.; Adey, E.; Xiong, T.; Champanerai, R.; et al. Laparoscopic uterine nerve ablation for alleviating chronic pelvic pain: A randomized controlled trial. *Jama* **2009**, *302*, 955–961. [CrossRef] [PubMed]

63. Boretto, M.; Cox, B.; Noben, M.; Hendriks, N.; Fassbender, A.; Roose, H.; Amant, F.; Timmerman, D.; Tomassetti, C.; Vanhie, A.; et al. Development of organoids from mouse and human endometrium showing endometrioid epithelium physiology and long-term expandability. *Development* **2017**, *144*, 1775–1786. [CrossRef] [PubMed]

64. Turco, M.Y.; Gardner, L.; Hughes, J.; Cindrova-Davies, T.; Gomez, M.J.; Farrell, L.; Hollinshead, M.; Marsh, S.G.E.; Brosens, J.J.; Critchley, H.O.; et al. Long-term, hormone-responsive organoid cultures of human endometrium in a chemically defined medium. *Nat. Cell Biol.* **2017**, *19*, 568–577. [CrossRef]

65. Boretto, M.; Maenhoudt, N.; Luo, X.; Boeckx, B.; Bui, B.; Heremans, R.; Perneel, L.; Kobayashi, H.; Van Zundert, I.; et al. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. *Nat. Cell Biol.* **2019**, *21*, 1041–1051. [CrossRef]

66. Andersson, S.; Sundberg, M.; Pristovsek, N.; Ibrahim, A.; Jonsson, P.; Katona, B.; Clausson, C.M.; Zieba, A.; Ramstrom, M.; Soderberg, O.; et al. Insufficient antibody validation challenges oestrogen receptor beta research. *Nat. Commun.* **2017**, *8*, 15840. [CrossRef]

67. Samartzis, N.; Samartzis, E.P.; Noske, A.; Fedier, A.; Dedes, K.J.; Cadu, R.; Fink, D.; Imesch, P. Expression of the G protein-coupled estrogen receptor (GPER) in endometriosis: A tissue microarray study. *Reprod. Biol. Endocrinol.* **2012**, *10*, 30. [CrossRef]

68. Plante, B.J.; Lessey, B.A.; Taylor, R.N.; Wang, W.; Bagchi, M.K.; Yang, L.; Scotchie, J.; Fritz, M.A.; Young, S.L. G protein-coupled estrogen receptor (GPER) expression in normal and abnormal endometrium. *Reprod. Sci.* **2012**, *19*, 684–693. [CrossRef]

69. Heublein, S.; Vrekoussis, T.; Kuhn, C.; Friese, K.; Makrigiannakis, A.; Mayr, D.; Lenhard, M.; Jeschke, U. Inducers of G-protein coupled estrogen receptor (GPER) in endometriosis: Potential implications for macrophages and follicle maturation. *J. Reprod. Immunol.* **2013**, *97*, 95–103. [CrossRef]

70. Bedaiwy, M.A.; Allaire, C.; Yong, P.; Alfaraj, S. Medical Management of Endometriosis in Patients with Chronic Pelvic Pain. *Semin. Reprod. Med.* **2017**, *35*, 38–53. [CrossRef]

71. Harris, H.A.; Bruner-Tran, K.L.; Zhang, X.; Osteen, K.G.; Lyttle, C.R. A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis. *Hum. Reprod.* **2005**, *20*, 936–941. [CrossRef] [PubMed]

72. Falconer, H.; Mwenda, J.M.; Chai, D.C.; Wagner, W.; Bagchi, M.K.; Yuan, L.; Scotchie, J.; Fritz, M.A.; Young, S.L. Adenosine A1 receptor agonist causes lesion regression in an experimentally induced model of endometriosis. *Semin. Reprod. Med.* **2017**, *35*, 38–53. [CrossRef]

73. Stratton, P.; Sinaii, N.; Segars, J.; Koziol, D.; Zimmer, C.; Winkel, C.; Nieman, L.K. Return of chronic pelvic pain from endometriosis after raloxifene treatment: A randomized controlled trial. *Obstet. Gynecol.* **2008**, *111*, 88–96. [CrossRef]

74. Kulak, J., Jr.; Fischer, C.; Komm, B.; Taylor, H.S. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. *Endocrinology* **2011**, *152*, 3226–3232. [CrossRef]

75. Naqvi, H.; Sakr, S.; Presti, T.; Krikun, G.; Komm, B.; Taylor, H.S. Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model. *Biol. Reprod.* **2014**, *90*, 121. [CrossRef]

76. Flores, V.A.; Leone, C.; Taylor, H.S.; Stachenfeld, N.S. Effects of bazedoxifene/conjugated estrogens on reproductive endocrinology and reproductive tract ultrasonographic appearance in premenopausal women: A preliminary study. *Gynecol. Endocrinol.* **2019**, *35*, 390–394. [CrossRef]
80. Khine, Y.M.; Taniguchi, F.; Nagira, K.; Nakamura, K.; Ohbayashi, T.; Osaki, M.; Harada, T. New insights into the efficacy of SR-16234, a selective estrogen receptor modulator, on the growth of murine endometriosis-like lesions. *Am. J. Reprod. Immunol.* 2018, 80, e13023. [CrossRef]
81. Streuli, I.; de Ziegler, D.; Santulli, P.; Marcellin, L.; Borghese, B.; Batteux, F.; Chapron, C. An update on the pharmacological management of endometriosis. *Expert Opin. Pharmacother.* 2013, 14, 291–305. [CrossRef] [PubMed]
82. Attar, E.; Bulun, S.E. Aromatase inhibitors: The next generation of therapeutics for endometriosis? *Fertil. Steril.* 2006, 85, 1307–1318. [CrossRef] [PubMed]
83. Abushahin, F.; Goldman, K.N.; Barbieri, E.; Milad, M.; Rademaker, A.; Bulun, S.E. Aromatase inhibition for refractory endometriosis-related chronic pelvic pain. *Fertil. Steril.* 2011, 96, 939–942. [CrossRef] [PubMed]
84. Amsterdam, L.L.; Gentry, W.; Jobanputra, S.; Wolf, M.; Rubin, S.D.; Bulun, S.E. Anastrozole and oral contraceptives: A novel treatment for endometriosis. *Fertil. Steril.* 2005, 84, 300–304. [CrossRef]
85. Takayama, K.; Zeitoun, K.; Gunby, R.T.; Sasano, H.; Carr, B.R.; Bulun, S.E. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. *Fertil. Steril.* 1998, 69, 709–713. [CrossRef]
86. Gargiulo, A.R.; Strauss, J.F.; Barbieri, R.L. *Yen & Jaffe’s Reproductive Endocrinology E-Book: Physiology, Pathophysiology, and Clinical Management*, 8th ed.; Elsevier: Amsterdam, The Netherlands, 2019; pp. 609–642.
87. Abdul Karim, A.K.; Shafiee, M.N.; Abd Aziz, M.H.; Lim, P.S.; Md Zin, R.R.; Mokhtar, N. Reviewing the role of progesterone therapy in endometriosis. *Gynecol. Endocrinol.* 2019, 35, 10–16. [CrossRef]
88. Bedaiwy, M.A.; Alfaraj, S.; Yong, P.; Casper, R. New developments in the medical treatment of endometriosis. *Fertil. Steril.* 2017, 107, 555–565. [CrossRef]
89. Zhang, T.; De Carolis, C.; Man, G.C.W.; Wang, C.C. The link between immunity, autoimmunity and endometriosis: A literature update. *Autoimmun. Rev.* 2018, 17, 945–955. [CrossRef]
90. Ferlita, A.; Battaglia, R.; Andronico, F.; Caruso, S.; Cianci, A.; Purrello, M.; Pietro, C.D. Non-Coding RNAs in Endometrial Physiopathology. *Int. J. Mol. Sci.* 2018, 19, 2120. [CrossRef]